Glenmark Recalls 1.5M ADHD Drug Bottles Over Carcinogen Risk
Glenmark Pharmaceuticals has recalled approximately 1.5 million bottles of Atomoxetine Capsules from the US market after tests found potentially harmful impurities above FDA-approved limits. The medication, used to treat attention deficit hyperactivity